What is target engagement and how is it measured in early drug discovery?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What is target engagement and how is it measured in early drug discovery?

Target engagement is about whether a drug actually binds to its intended molecular target in a biological system. In early drug discovery, confirming this binding helps show that the compound reaches and interacts with the target at feasible doses, which is essential before moving toward efficacy studies. You measure target engagement in several ways: biochemical assays quantify how tightly and effectively the drug binds or inhibits the target in vitro; occupancy studies estimate the fraction of target molecules occupied by the drug in cells or tissues; and imaging biomarkers, such as PET or other imaging readouts, visualize target occupancy in living organisms. These approaches together tell you if the drug is engaging the intended target, which guides dosing decisions and compound optimization. The other concepts are about different aspects of drug development. Time to peak plasma concentration is a pharmacokinetic measure of how quickly the drug reaches the bloodstream and peaks, not whether it binds the target. Cost-effectiveness concerns value and economics in a population, and patient adherence relates to how well patients follow the prescribed regimen.

Target engagement is about whether a drug actually binds to its intended molecular target in a biological system. In early drug discovery, confirming this binding helps show that the compound reaches and interacts with the target at feasible doses, which is essential before moving toward efficacy studies. You measure target engagement in several ways: biochemical assays quantify how tightly and effectively the drug binds or inhibits the target in vitro; occupancy studies estimate the fraction of target molecules occupied by the drug in cells or tissues; and imaging biomarkers, such as PET or other imaging readouts, visualize target occupancy in living organisms. These approaches together tell you if the drug is engaging the intended target, which guides dosing decisions and compound optimization.

The other concepts are about different aspects of drug development. Time to peak plasma concentration is a pharmacokinetic measure of how quickly the drug reaches the bloodstream and peaks, not whether it binds the target. Cost-effectiveness concerns value and economics in a population, and patient adherence relates to how well patients follow the prescribed regimen.

More practice questions